MedWatch

Ambu downgrades due to covid-19 and logistical challenges

The medtech firm is downgrading its annual guidance as operations and the firm's logistics chain are still being affected by the pandemic.

Photo: PR / Ambu

On Thursday evening, the medtech company lowered its guidance, as the covid-19 pandemic continues to affect the number of operations being performed while also disrupting the firm's supply chain, according to an Ambu press release.

Now, Ambu expects to realize organic growth in 2021/2022 at around 17 percent compared to 17-20 percent previously forecast. It predicts that the earnings before interest an taxes will be around 10 percent, compared to 11-12 percent predicted previously.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs